IP-10 in autoimmune thyroiditis

Hormone and Metabolic Research

Volumn 46, Issue 9, 2014, Pages 597-602

  Ruffilli, I ^a   Ferrari, S M ^a   Colaci, M ^b   Ferri, C ^b   Fallahi, P ^a   Antonelli, A ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

CXCL10; CXCR3; thyroid autoantibodies; thyroid autoimmunity

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; CXCL10 PROTEIN, HUMAN;

AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; CYTOKINE RELEASE; HASHIMOTO DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; THYROID CANCER; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY;

AUTOIMMUNITY; CHEMOKINE CXCL10; HUMANS; THYROIDITIS, AUTOIMMUNE;

EID: 84906306942     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1382053     Document Type: Review

References (86)

1. Allen S. J., Crown S. E., Handel T. M. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol: 2007; 25 787 820
2. Ohmori Y., Hamilton T. A. The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. J Immunol: 1995; 154 5235 5244
3. Shields P. L., Morland C. M., Salmon M., Qin S., Hubscher S. G., Adams D. H. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol: 1999; 163 6236 6243
4. Dillman J. F. 3rd, McGary K. L., Schlager J. J. An inhibitor of p38 MAP kinase downregulates cytokine release induced by sulfur mustard exposure in human epidermal keratinocytes. Toxicol In Vitro: 2004; 18 593 599
5. Ohmori Y., Hamilton T. A. Cell type and stimulus specific regulation of chemokine gene expression. Biochem Biophys Res Commun: 1994; 198 590 596
6. Ge M. Q., Ho A. W., Tang Y., Wong K. H., Chua B. Y., Gasser S., Kemeny D. M. NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza A infection by IFN-gamma and perforin-dependent mechanisms. J Immunol: 2012; 189 2099 2109
7. Moodley K., Angel C. E., Glass M., Graham E. S. Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. J Neurosci Methods: 2011; 200 173 180
8. Antonelli A., Ferrari S. M., Giuggioli D., Ferrannini E., Ferri C., Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev: 2014; 13 272 280
9. Jinquan T., Jing C., Jacobi H. H., Reimert C. M., Millner A., Quan S., Hansen J. B., Dissing S., Malling H. J., Skov P. S., Poulsen L. K. CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. J Immunol: 2000; 165 1548 1556
10. Taub D. D., Lloyd A. R., Conlon K., Wang J. M., Ortaldo J. R., Harada A., Matsushima K., Kelvin D. J., Oppenheim J. J. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med: 1993; 177 1809 1814
11. Engel M. A., Neurath M. F. Anticancer properties of the IL-12 family - focus on colorectal cancer. Curr Med Chem: 2010; 17 3303 3308
12. Antonelli A., Ferri C., Ferrari S. M., Colaci M., Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev: 2008; 8 18 23
13. Antonelli A., Rotondi M., Fallahi P., Ferrari S. M., Paolicchi A., Romagnani P., Serio M., Ferrannini E. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine: 2006; 34 32 38
14. Antonelli A., Rotondi M., Fallahi P., Grosso M., Boni G., Ferrari S. M., Romagnani P., Serio M., Mariani G., Ferrannini E. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab: 2007; 92 1485 1490
15. Antonelli A., Ferrari S. M., Fallahi P., Frascerra S., Santini E., Franceschini S. S., Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab: 2009; 94 1803 1809
16. Antonelli A., Fallahi P., Nesti C., Pupilli C., Marchetti P., Takasawa S., Okamoto H., Ferrannini E. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol: 2001; 126 426 431
17. Antonelli A., Baj G., Marchetti P., Fallahi P., Surico N., Pupilli C., Malavasi F., Ferrannini E. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes: 2001; 50 985 991
18. Antonelli A., Tuomi T., Nannipieri M., Fallahi P., Nesti C., Okamoto H., Groop L., Ferrannini E. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia: 2002; 45 1298 1306
19. Antonelli A., Fallahi P., Ferrari S. M., Pupilli C., d'Annunzio G., Lorini R., Vanelli M., Ferrannini E. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med: 2008; 25 1349 1353
20. Cossu A., Ferrannini E., Fallahi P., Antonelli A., Sechi L. A. Antibodies recognizing specific Mycobacterium avium subsp. paratuberculosis's MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. Cytokine: 2013; 61 337 339
21. Antonelli A., Ferrari S. M., Corrado A., Ferrannini E., Fallahi P. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev: 2014; 25 57 65
22. Lee E. Y., Lee Z. H., Song Y. W. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev: 2013; 12 554 557
23. Lacotte S., Brun S., Muller S., Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci: 2009; 1173 310 317
24. Antonelli A., Ferri C., Fallahi P., Ferrari S. M., Giuggioli D., Colaci M., Manfredi A., Frascerra S., Franzoni F., Galetta F., Ferrannini E. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis - a longitudinal study. Rheumatology (Oxford): 2008; 47 45 49
25. Antonelli A., Ferri C., Fallahi P., Colaci M., Giuggioli D., Ferrari S. M., Frascerra S., Franzoni F., Galetta F., Ferrannini E. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol: 2008; 35 1809 1811
26. Antonelli A., Delle Sedie A., Fallahi P., Ferrari S. M., Maccheroni M., Ferrannini E., Bombardieri S., Riente L. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J Rheumatol: 2006; 33 2026 2028
27. Antonelli A., Fallahi P., Delle Sedie A., Ferrari S. M., Maccheroni M., Bombardieri S., Riente L., Ferrannini E. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity: 2008; 41 537 542
28. Antonelli A., Fallahi P., Delle Sedie A., Ferrari S. M., Maccheroni M., Bombardieri S., Riente L., Ferrannini E. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol: 2009; 27 22 27
29. Antonelli A., Fazzi P., Fallahi P., Ferrari S. M., Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest: 2006; 130 526 532
30. Su R., Nguyen M. L., Agarwal M. R., Kirby C., Nguyen C. P., Ramstein J., Darnell E. P., Gomez A. D., Ho M., Woodruff P. G., Koth L. L. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res: 2013; 14 121
31. Antonelli A., Ferri C., Fallahi P., Giuggioli D., Nesti C., Longombardo G., Fadda P., Pampana A., Maccheroni M., Ferrannini E. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM: 2004; 97 499 506
32. Antonelli A., Ferri C., Fallahi P., Ferrari S. M., Sebastiani M., Ferrari D., Giunti M., Frascerra S., Tolari S., Franzoni F., Galetta F., Marchi S., Ferrannini E. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol: 2008; 103 2488 2494
33. Ferri C., Antonelli A., Mascia M. T., Sebastiani M., Fallahi P., Ferrari D., Pileri S. A., Zignego A. L. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis: 2007; 39 01 S13 S21
34. Ferri C., Antonelli A., Mascia M. T., Sebastiani M., Fallahi P., Ferrari D., Giunti M., Pileri S. A., Zignego A. L. B-cells and mixed cryoglobulinemia. Autoimmun Rev: 2007; 7 114 120
35. Tozzoli R., Barzilai O., Ram M., Villalta D., Bizzaro N., Sherer Y., Shoenfeld Y. Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev: 2008; 8 112 115
36. Burek C. L., Rose N. R. Autoimmune thyroiditis and ROS. Autoimmun Rev: 2008; 7 530 537
37. McLachlan S. M., Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev: 2014; 35 59 105
38. Guarneri F., Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Endocrinol Diabetes Obes: 2007; 14 398 409
39. Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol: 2014; 9 147 156
40. McLeod D. S., Cooper D. S. The incidence and prevalence of thyroid autoimmunity. Endocrine: 2012; 42 252 265
41. Benvenga S., Trimarchi F. Changed presentation of Hashimoto's thyroiditis in North-Eastern Sicily and Calabria (Southern Italy) based on a 31-year experience. Thyroid: 2008; 18 429 441
42. Rizzo M., Rossi R. T., Bonaffini O., Scisca C., Altavilla G., Calbo L., Rosanò A., Sindoni A., Trimarchi F., Benvenga S. Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. Ann Endocrinol (Paris): 2010; 71 525 534
43. Weetman A. P. Cellular immune responses in autoimmune thyroid disease. Clin Endocrinol (Oxf): 2004; 61 405 413
44. Nanba T., Watanabe M., Inoue N., Iwatani Y. Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease. Thyroid: 2009; 19 495 501
45. Figueroa-Vega N., Alfonso-Pérez M., Benedicto I., Sánchez-Madrid F., González-Amaro R., Marazuela M. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. J Clin Endocrinol Metab: 2010; 95 953 962
46. Li D., Cai W., Gu R., Zhang Y., Zhang H., Tang K., Xu P., Katirai F., Shi W., Wang L., Huang T., Huang B. Th17 cell plays a role in the pathogenesis of Hashimoto's thyroiditis in patients. Clin Immunol: 2013; 149 411 420
47. García-López M. A., Sancho D., Sánchez-Madrid F., Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab: 2001; 86 5008 5016
48. Kemp E. H., Metcalfe R. A., Smith K. A., Woodroofe M. N., Watson P. F., Weetman A. P. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf): 2003; 59 207 213
49. Kimura H., Kimura M., Rose N. R., Caturegli P. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto's thyroiditis. Exp Mol Pathol: 2004; 77 161 167
50. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S. M., Buonamano A., Ferrannini E., Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab: 2004; 89 5496 5499
51. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S. M., Paolicchi A., Ferrannini E., Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol: 2005; 152 171 177
52. Antonelli A., Ferri C., Fallahi P., Ferrari S. M., Frascerra S., Sebastiani M., Franzoni F., Galetta F., Ferrannini E. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine: 2008; 42 137 143
53. Antonelli A., Ferri C., Fallahi P., Ferrari S. M., Frascerra S., Carpi A., Nicolini A., Ferrannini E. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism: 2008; 57 1270 1277
54. Antonelli A., Ferri C., Fallahi P., Ferrari S. M., Frascerra S., Pampana A., Panicucci E., Carpi A., Nicolini A., Ferrannini E. CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. J Interferon Cytokine Res: 2009; 29 345 351
55. Antonelli A., Ferri C., Ferrari S. M., De Marco S., Di Domenicantonio A., Centanni M., Pupilli C., Villa E., Menichetti F., Fallahi P. Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. J Interferon Cytokine Res: 2010; 30 835 842
56. Antonelli A., Ferri C., Ferrari S. M., Colaci M., Sansonno D., Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab: 2009; 5 26 34
57. Antonelli A., Fallahi P., Rotondi M., Ferrari S. M., Romagnani P., Grosso M., Ferrannini E., Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol: 2006; 154 651 658
58. Antonelli A., Ferrari S. M., Frascerra S., Galetta F., Franzoni F., Corrado A., Miccoli M., Benvenga S., Paolicchi A., Ferrannini E., Fallahi P. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine: 2011; 55 288 293
59. Antonelli A., Fallahi P., Ferrari S. M., Sebastiani M., Manfredi A., Mazzi V., Fabiani S., Centanni M., Marchi S., Ferri C. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol: 2012; 22 659 667
60. Antonelli A., Ferri C., Ferrari S. M., Frascerra S., Ruffilli I., Caponi L., Ulisse S., Miccoli M., Miccoli P., Fallahi P. High levels of circulating chemokine (C-X-C motif) ligand 11 are associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis and with chemokine (C-X-C motif) ligand 10. J Interferon Cytokine Res: 2012; 32 74 80
61. Groom J. R., Luster A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol: 2011; 89 207 215
62. Antonelli A., Rotondi M., Ferrari S. M., Fallahi P., Romagnani P., Franceschini S. S., Serio M., Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab: 2006; 91 614 620
63. Rotondi M., Coperchini F., Pignatti P., Sideri R., Groppelli G., Leporati P., La Manna L., Magri F., Mariotti S., Chiovato L. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation? J Clin Endocrinol Metab: 2013; 98 308 313
64. Benvenga S. On the association between Hashimoto's thyroiditis and papillary thyroid carcinoma: looking 100 years back and, hopefully, fewer years ahead to sort out this association. Thyroid: 2013; 23 1180 1181
65. Jankovic B., Le K. T., Hershman J. M. Clinical Review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab: 2013; 98 474 482
66. Fiore E., Rago T., Latrofa F., Provenzale M. A., Piaggi P., Delitala A., Scutari M., Basolo F., Di Coscio G., Grasso L., Pinchera A., Vitti P. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with l -thyroxine. Endocr Relat Cancer: 2011; 18 429 437
67. Antonelli A., Ferri C., Fallahi P., Nesti C., Zignego A. L., Maccheroni M. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol: 2002; 20 693 696
68. Antonelli A., Ferri C., Fallahi P., Pampana A., Ferrari S. M., Barani L., Marchi S., Ferrannini E. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid: 2007; 17 447 451
69. Antonelli A., Miccoli P., Derzhitski V. E., Panasiuk G., Solovieva N., Baschieri L. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). World J Surg: 1996; 20 867 871
70. Antonelli A., Fallahi P., Ferrari S. M., Carpi A., Berti P., Materazzi G., Minuto M., Guastalli M., Miccoli P. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed Pharmacother: 2008; 62 559 563
71. Neri S., Boraschi P., Antonelli A., Falaschi F., Baschieri L. Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. Am J Ind Med: 1996; 30 588 595
72. Spinelli C., Bertocchini A., Antonelli A., Miccoli P. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients
73. Melillo R. M., Castellone M. D., Guarino V., De Falco V., Cirafici A. M., Salvatore G., Caiazzo F., Basolo F., Giannini R., Kruhoffer M., Orntoft T., Fusco A., Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest: 2005; 115 1068 1081
74. Antonelli A., Ferrari S. M., Fallahi P., Frascerra S., Piaggi S., Gelmini S., Lupi C., Minuto M., Berti P., Benvenga S., Basolo F., Orlando C., Miccoli P. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer: 2009; 16 1299 1311
75. Melillo R. M., Guarino V., Avilla E., Galdiero M. R., Liotti F., Prevete N., Rossi F. W., Basolo F., Ugolini C., de Paulis A., Santoro M., Marone G. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene: 2010; 29 6203 6215
76. Proudfoot A. E., Power C. A., Rommel C., Wells T. N. Strategies for chemokine antagonists as therapeutics. Semin Immunol: 2003; 15 57 65
77. Gosset P., Charbonnier A. S., Delerive P., Fontaine J., Staels B., Pestel J., Tonnel A. B., Trottein F. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol: 2001; 31 2857 2865
78. Marx N., Mach F., Sauty A., Leung J. H., Sarafi M. N., Ransohoff R. M., Libby P., Plutzky J., Luster A. D. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol: 2000; 164 6503 6508
79. Schaefer K. L., Denevich S., Ma C., Cooley S. R., Nakajima A., Wada K., Schlezinger J., Sherr D., Saubermann L. J. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis: 2005; 11 244 252
80. Antonelli A., Ferrari S. M., Fallahi P., Piaggi S., Paolicchi A., Franceschini S. S., Salvi M., Ferrannini E. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism: 2011; 60 277 283
81. Oliveira A. C., Bertollo C. M., Rocha L. T., Nascimento E. B. Jr, Costa K. A., Coelho M. M. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol: 2007; 561 194 201
82. Spencer N. F., Poynter M. E., Im S. Y., Daynes R. A. Constitutive activation of NF-kappa B in an animal model of aging. Int Immunol: 1997; 9 1581 1588
83. Lee J. W., Bajwa P. J., Carson M. J., Jeske D. R., Cong Y., Elson C. O., Lytle C., Straus D. S. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10 deficient mice. Gastroenterology: 2007; 133 108 123
84. Antonelli A., Ferrari S. M., Frascerra S., Corrado A., Pupilli C., Bernini G., Benvenga S., Ferrannini E., Fallahi P. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Exp Cell Res: 2011; 317 1527 1533
85. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J. M., Gonzalez F. J., Fruchart J. C., Tedgui A., Haegeman G., Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem: 1999; 274 32048 32054
86. Pascual G., Fong A. L., Ogawa S., Gamliel A., Li A. C., Perissi V., Rose D. W., Willson T. M., Rosenfeld M. G., Glass C. K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature: 2005; 437 759 763